The aim of this study was to assess the efficacy and safety of erlotinib, an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as second‑or third‑line treatment for …

Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …

Background: As the incidence of lung cancer in the elderly is increasing worldwide, there
exists a need to develop a clinically effective, less toxic therapy for this patient population …

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Efficacy of
this drug was documented in the BR. 21 trial showing that adenocarcinoma, female gender …

Purpose To evaluate the efficacy and toxicities of erlotinib as first-line treatment for Asian
elderly patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods …

19016 Background: The prognosis for elderly pts with advanced NSCLC is generally poor
due to significant co-morbidities that limit treatment options. Furthermore, aggressive …

The incidence and mortality of lung cancer have increased worldwide over the last decades,
with an observed increased incidence particularly among elderly populations. It has not yet …

Purpose National Cancer Institute of Canada Clinical Trials Group Study BR. 21 established
erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after …

In order to evaluate the clinical efficacy and the safety profile of molecularly targeted
therapies as a palliative approach in elderly populations affected by advanced thoracic …

Abstract Tarceva Lung cancer Survival Treatment (TRUST) was an open-label, phase IV
study of advanced non-small cell lung cancer (NSCLC). Patients failing or unsuitable for …